Ischemic heart diseases with PIC
Conditions
Interventions
Sponsors
Kazuo Umemura Center for clinical research Hamamatsu University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Japanese 2.From 20 years old to 45 years old at voluntary written consent 3.From 50.0 kg to 85.0 kg and from 18.5 to 25.0 of BMI at screening 4.Voluntary written consent by themselves is given before screening
Exclusion criteria
Exclusion criteria: 1.History of liver diseases, cardiovascular diseases, respiratory diseaases, gastroenteric diseases, kidney diseases, cerebralvascular diseases, cancer 2.Known hypersensitivity to some drugs and foods 3.Under normal range in platelet counts at screning 4.Treatment by other doctors (included supplement) within 14 days before screening 5.Treatment with any investigational compound within 120 days before screening 6.History of blood taken *>= 1200ml of all blood within 1 year before screening *>= 400ml of all blood with 84 days before screening *>= 200ml of all blood within 14 days before screening 7.Known active chronic hepatitis B or C, active syphilis and human immunodeficiency virus infection 8.Abuse of alcohol or drugs (included past history) 9.Bleeding, in the tendency to bleeding, and family history and past history of bleeding disorders 10.During pregnancy and possibility of pregnancy and lactation period 11.Any serious medical or psychiatric illness that could, in the opinion of the investigator, potentially interfere with the completion of treatment according to this protocol.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pharmacodynamics of clopidogrel and prasugrel | — |
Secondary
| Measure | Time frame |
|---|---|
| Pharmacokinetics of clopidogrel and prasugrel | — |
Countries
Japan
Contacts
Public Contactkazuo umemura
Center for clinical research, Hamamatsu University hoapital Translational center
Outcome results
None listed